Leuprolide
Main evidence: Human clinical trials. Updated 2026-10-28.
What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.
Summary
Leuprolide (leuprorelin) is a gonadotropin-releasing hormone agonist supplied in formulation-specific depot medicines. The Australian Lucrin PDS product and the TGA-assessed Eligard formulation differ in route, indication, release system, and supplied diluent. Clinical-trial findings and instructions for one formulation should not be transferred to another.
What the sources say
- In a human trial of a six-month intramuscular leuprolide depot in men with prostate cancer, 93.4% of subjects achieved the study testosterone-suppression endpoint. The trial supports biochemical suppression for that studied formulation, not interchangeability across products or routes. (Human clinical trials; Spitz et al., "Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer", 2011-10-25)
- The Australian Lucrin PDS product information lists adult use for palliative treatment of metastatic or locally advanced prostate cancer and a separate paediatric presentation for central precocious puberty. These indications apply to the named presentations, not automatically to every leuprorelin product. (Manufacturer information; LUCRIN Depot and LUCRIN Depot Paediatric (leuprorelin acetate), prefilled dual-chamber syringe injection, Australian Product Information, Version 19 (21 February 2025), 2025-02-21)
- The Australian Lucrin PDS information identifies the adult and paediatric presentations as separate products that should not be substituted for one another. (Manufacturer information; LUCRIN Depot and LUCRIN Depot Paediatric (leuprorelin acetate), prefilled dual-chamber syringe injection, Australian Product Information, Version 19 (21 February 2025), 2025-02-21)
- GnRH-agonist treatment can initially increase testosterone and worsen bone pain, urinary obstruction, haematuria, neurologic symptoms, or spinal-cord compression in vulnerable patients. The Australian product information requires physician supervision; paediatric central precocious puberty treatment requires specialist oversight. (Manufacturer information; Therapeutic Goods Administration, Attachment 1: Product Information for AusPAR Eligard, finalised 2018-09-05, 2018-09-05)
- The Australian Eligard information also identifies hyperglycaemia or diabetes, cardiovascular events, QT prolongation, bone-density loss, and post-marketing seizures as relevant cautions. This risk summary is not a personal monitoring plan. (Manufacturer information; Therapeutic Goods Administration, Attachment 1: Product Information for AusPAR Eligard, finalised 2018-09-05, 2018-09-05)
Sources
- Spitz et al., "Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer" (2011-10-25)
- LUCRIN Depot and LUCRIN Depot Paediatric (leuprorelin acetate), prefilled dual-chamber syringe injection, Australian Product Information, Version 19 (21 February 2025) (2025-02-21)
- Therapeutic Goods Administration, Attachment 1: Product Information for AusPAR Eligard, finalised 2018-09-05 (2018-09-05)
Dosing, stacking and protocol details are not published here.